|
|||||
|
|
Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.“ |
|
| Authors: | Jim Abraham Chadi Nabhan Matthew Oberley Wolfgang Michael Korn David Spetzler |
| Affiliation: | aCaris Life Sciences, Phoenix, AZ;bArizona State University, Phoenix, AZ;cUniversity of South Carolina, Department of Clinical Pharmacy and Outcomes Sciences, Columbia, SC;dUniversity of California in San Francisco, Division of Hematology and Oncology, San Francisco, CA |
| Abstract: | |
| Keywords: | |